{
  "guideline" : {
    "objCls" : "Guideline",
    "@id" : "https://api.pharmgkb.org/data/guideline/PA166109594",
    "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
    "id" : "PA166109594",
    "name" : "CPIC Guideline for capecitabine and DPYD",
    "history" : [ {
      "id" : 1183699767,
      "date" : "2013-08-29T00:00:00-07:00",
      "type" : "create",
      "version" : 0
    }, {
      "id" : 1184511811,
      "date" : "2014-07-30T00:00:00-07:00",
      "description" : "created individual pages for tegafur and fluorouracil and took those drugs off of this guideline",
      "type" : "update",
      "version" : 1
    }, {
      "id" : 1184511804,
      "date" : "2014-07-30T00:00:00-07:00",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1184513259,
      "date" : "2014-08-06T00:00:00-07:00",
      "description" : "updated extended dosing guidelines to include *4, *5, *6, *9A",
      "type" : "update",
      "version" : 1
    } ],
    "relatedChemicals" : [ {
      "objCls" : "Chemical",
      "@id" : "https://api.pharmgkb.org/data/chemical/PA448771",
      "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
      "id" : "PA448771",
      "name" : "capecitabine",
      "version" : 53
    } ],
    "relatedGenes" : [ {
      "objCls" : "Gene",
      "@id" : "https://api.pharmgkb.org/data/gene/PA145",
      "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
      "id" : "PA145",
      "symbol" : "DPYD",
      "name" : "dihydropyrimidine dehydrogenase",
      "version" : 6954
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447981840,
      "externalLinks" : [ ],
      "html" : "<p>The CPIC Dosing Guidelines for fluoropyrimidines (i.e. 5-fluorouracil, capecitabine or tegafur) recommends an alternative drug for patients who are homozygous for DPYD non-functional variants - *2A (<a href=\"/variant/PA166153760\">rs3918290</a>), *13 (<a href=\"/variant/PA166153888\">rs55886062</a>), and <a href=\"/variant/PA166153895\">rs67376798</a> A (on the positive chromosomal strand) - as these patients are typically DPD deficient.  Consider a 50% reduction in starting dose for heterozygous patients (intermediate activity).</p>\n",
      "internalLinks" : [ ],
      "markdown" : "The CPIC Dosing Guidelines for fluoropyrimidines (i.e. 5-fluorouracil, capecitabine or tegafur) recommends an alternative drug for patients who are homozygous for DPYD non-functional variants - *2A ([variant:rs3918290]), *13 ([variant:rs55886062]), and [variant:rs67376798] A (on the positive chromosomal strand) - as these patients are typically DPD deficient.  Consider a 50% reduction in starting dose for heterozygous patients (intermediate activity).",
      "pmids" : [ ],
      "relatedObjects" : [ "PA166153760", "PA166153888", "PA166153895" ],
      "version" : 10
    },
    "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
    "textMarkdown" : {
      "id" : 1447981839,
      "externalLinks" : [ "http://www.ncbi.nlm.nih.gov/pubmed/?term=24648345", "https://cpicpgx.org/", "https://github.com/PharmGKB/cpic-guidelines/raw/master/fluoropyrimidines/2013/23988873-supplement.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/fluoropyrimidines/2013/23988873.pdf" ],
      "html" : "<h3 id=\"may-2014-update-on-pharmgkb\">May 2014 Update on PharmGKB</h3>\n<ul>\n<li>The CPIC authors recommend that the <em>DPYD*4</em>, <em>*5</em>, <em>*6</em> and <em>*9A</em> alleles be categorized as &quot;normal&quot; activity, in part based upon the recent publication <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F%3Fterm%3D24648345\" target=\"_blank\">Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity</a>.</li>\n</ul>\n<h3 id=\"december-2013-publication\">December 2013 Publication</h3>\n<p><em>Accepted article preview online August 2013; Advance online publication October 2013.</em></p>\n<ul>\n<li>Guidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in <em>Clinical Pharmacology and Therapeutics</em> by the Clinical Pharmacogenetics Implementation Consortium <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2F\" target=\"_blank\">(CPIC)</a>.</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>at the time of this writing, there are no data available on the possible role of DPYD*2A, *13, or <a href=\"/variant/PA166153895\">rs67376798</a> in 5-fluorouracil toxicities in pediatric patient populations; however, there is no reason to suspect that DPYD variant alleles would affect 5-fluorouracil metabolism differently in children compared to adults.</li>\n</ul>\n</li>\n<li>Excerpt from the fluoropyrimidine dosing guideline based on DPYD genotype:\n<ul>\n<li>&quot;The strength of the dosing recommendations is based on the fact that some variants (DPYD*2A, *13, and <a href=\"/variant/PA166153895\">rs67376798</a>) clearly affect DPD activity, and DPD activity is clearly related to 5-fluorouracil clearance, and 5-fluorouracil exposure is associated with its toxic effects. Therefore, reduction of fluoropyrimidine dosage in patients with these variants may prevent severe and possibly life-threatening toxicities. However, available evidence does not clearly indicate a degree of dose reduction needed to prevent fluoropyrimidine related toxicities...[Based on literature review (see full manuscript),] our recommendation is to start with at least a 50% reduction of the starting dose followed by an increase in dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy, a decrease in dose in patients who do not tolerate the starting dose to minimize toxicities or pharmacokinetic guided dose adjustments (if available). Patients who are homozygous for DPYD*2A, *13, or <a href=\"/variant/PA166153895\">rs67376798</a> may demonstrate complete DPD deficiency and the use of 5-fluorouracil or capecitabine is not recommended in these patients.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Ffluoropyrimidines%2F2013%2F23988873.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Ffluoropyrimidines%2F2013%2F23988873-supplement.pdf\" target=\"_blank\">2013 supplement</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-recommended-dosing-of-fluoropyrimidines-by-genotype-phenotype\">Table 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.</h3>\n<p><em>Adapted from Tables 1 and 2 of the 2013 guideline manuscript.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Phenotype (genotype)</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Dosing recommendations</th><th>Classification of recommendations <sup>a</sup></th></tr>\n</thead>\n<tbody>\n<tr><td>Homozygous wild-type or normal, high DPD activity (two or more functional *1 alleles)</td><td>*1/*1</td><td>Normal DPD activity and &quot;normal&quot; risk for fluoropyrimidine toxicity</td><td>Use label-recommended dosage and administration</td><td>Moderate</td></tr>\n<tr><td>Heterozygous or intermediate activity (~3-5% of patients), may have partial DPD deficiency, at risk for toxicity with drug exposure (one functional allele *1, plus one nonfunctional allele - *2A, *13 or rs67376798A <sup>c</sup>)</td><td>*1/*2A; *1/*13; *1/ rs67376798A <sup>c</sup>)</td><td>Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Start with at least a 50% reduction in starting dose followed by titration of dose based on toxicity <sup>b</sup> or pharmacokinetic test (if available)</td><td>Moderate</td></tr>\n<tr><td>Homozygous variant, DPD deficiency (~0.2% of patients), at risk for toxicity with drug exposure (2 nonfunctional alleles - *2A, *13 or rs67376798A <sup>c</sup>)</td><td>*2A/*2A; *13/*13; rs67376798A <sup>c</sup> / rs67376798A <sup>c</sup></td><td>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Select alternate drug</td><td>Strong</td></tr>\n</tbody>\n</table>\n<p><sup>a</sup> Rating scheme described in 2013 supplement.</p>\n<p><sup>b</sup> Increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.</p>\n<p><sup>c</sup> Note that the rs67376798A allele refers to the allele on the positive chromosomal strand.  This is important because DPYD is on the minus chromosomal strand and <a href=\"/variant/PA166153895\">rs67376798</a> is a T/A snp.  Therefore, the T allele on the gene confers the deficiency, while the complement on the positive chromosomal strand (A allele) is indicative of deficiency.</p>\n",
      "internalLinks" : [ ],
      "markdown" : "##  May 2014 Update on PharmGKB\r\n- The CPIC authors recommend that the _DPYD*4_, _*5_, _*6_ and _*9A_ alleles be categorized as \"normal\" activity, in part based upon the recent publication [Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity](http://www.ncbi.nlm.nih.gov/pubmed/?term=24648345). \r\n\r\n## December 2013 Publication\r\n\r\n_Accepted article preview online August 2013; Advance online publication October 2013._\r\n- Guidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in _Clinical Pharmacology and Therapeutics_ by the Clinical Pharmacogenetics Implementation Consortium [(CPIC)](https://cpicpgx.org/).\r\n- These guidelines are applicable to:\r\n  - at the time of this writing, there are no data available on the possible role of DPYD*2A, *13, or [variant:rs67376798] in 5-fluorouracil toxicities in pediatric patient populations; however, there is no reason to suspect that DPYD variant alleles would affect 5-fluorouracil metabolism differently in children compared to adults.\r\n- Excerpt from the fluoropyrimidine dosing guideline based on DPYD genotype:\r\n  - \"The strength of the dosing recommendations is based on the fact that some variants (DPYD*2A, *13, and [variant:rs67376798]) clearly affect DPD activity, and DPD activity is clearly related to 5-fluorouracil clearance, and 5-fluorouracil exposure is associated with its toxic effects. Therefore, reduction of fluoropyrimidine dosage in patients with these variants may prevent severe and possibly life-threatening toxicities. However, available evidence does not clearly indicate a degree of dose reduction needed to prevent fluoropyrimidine related toxicities...\\[Based on literature review (see full manuscript),] our recommendation is to start with at least a 50% reduction of the starting dose followed by an increase in dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy, a decrease in dose in patients who do not tolerate the starting dose to minimize toxicities or pharmacokinetic guided dose adjustments (if available). Patients who are homozygous for DPYD*2A, *13, or [variant:rs67376798] may demonstrate complete DPD deficiency and the use of 5-fluorouracil or capecitabine is not recommended in these patients.\" \r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing](https://github.com/PharmGKB/cpic-guidelines/raw/master/fluoropyrimidines/2013/23988873.pdf)\r\n  - [2013 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/fluoropyrimidines/2013/23988873-supplement.pdf)\r\n\r\n##  Table 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.\r\n\r\n_Adapted from Tables 1 and 2 of the 2013 guideline manuscript._\r\n\r\n| Phenotype (genotype) | Examples of diplotypes | Implications for phenotypic measures | Dosing recommendations | Classification of recommendations ^a^ |\r\n| --- | --- | --- | --- | --- |\r\n| Homozygous wild-type or normal, high DPD activity (two or more functional *1 alleles) | *1/*1 | Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity | Use label-recommended dosage and administration | Moderate |\r\n| Heterozygous or intermediate activity (~3-5% of patients), may have partial DPD deficiency, at risk for toxicity with drug exposure (one functional allele *1, plus one nonfunctional allele - *2A, *13 or rs67376798A ^c^) | *1/*2A; *1/*13; *1/ rs67376798A ^c^) | Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs | Start with at least a 50% reduction in starting dose followed by titration of dose based on toxicity ^b^ or pharmacokinetic test (if available) | Moderate |\r\n| Homozygous variant, DPD deficiency (~0.2% of patients), at risk for toxicity with drug exposure (2 nonfunctional alleles - *2A, *13 or rs67376798A ^c^) | *2A/*2A; *13/*13; rs67376798A ^c^ / rs67376798A ^c^ | Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs | Select alternate drug | Strong |\r\n\r\n^a^ Rating scheme described in 2013 supplement.\r\n\r\n^b^ Increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.\r\n\r\n^c^ Note that the rs67376798A allele refers to the allele on the positive chromosomal strand.  This is important because DPYD is on the minus chromosomal strand and [variant:rs67376798] is a T/A snp.  Therefore, the T allele on the gene confers the deficiency, while the complement on the positive chromosomal strand (A allele) is indicative of deficiency.",
      "pmids" : [ ],
      "relatedObjects" : [ "PA166153895" ],
      "version" : 10
    },
    "version" : 78,
    "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983463,"resource":"Web Resource","sameAs":"https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-fluoropyrimidines-and-dpyd%2F","xrefId":"https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"} ]
  },
  "annotationGroups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166162687",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166162687",
    "name" : "Indeterminate",
    "annotations" : [ {
      "id" : 1448589747,
      "history" : [ {
        "id" : 1448589745,
        "date" : "2017-02-06T10:28:09.840-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589746,
        "externalLinks" : [ ],
        "html" : "<p>N/A</p>\n",
        "internalLinks" : [ ],
        "markdown" : "N/A",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448589750,
      "history" : [ {
        "id" : 1448589748,
        "date" : "2017-02-06T10:28:41.437-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589749,
        "externalLinks" : [ ],
        "html" : "<p>Indeterminate</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Indeterminate",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448589744,
      "history" : [ {
        "id" : 1448589742,
        "date" : "2017-02-06T10:27:50.450-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589743,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying one or two probably decreased function alleles.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying one or two probably decreased function alleles.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448589753,
      "history" : [ {
        "id" : 1448589751,
        "date" : "2017-02-06T10:29:37.622-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589752,
        "externalLinks" : [ ],
        "html" : "<p>This guideline does not contain recommendations for this allele combination.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "This guideline does not contain recommendations for this allele combination.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 0
    } ],
    "genePhenotypes" : [ "DPYD:No Function/Probable Decreased Function", "DPYD:Normal Function/Probable Decreased Function", "DPYD:Probable Decreased Function/Probable Decreased Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166109594",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166109594",
      "name" : "CPIC Guideline for capecitabine and DPYD",
      "version" : 78
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "version" : 7
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128872",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128872",
    "name" : "Normal Metabolizer",
    "annotations" : [ {
      "id" : 1446441370,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986595,
        "externalLinks" : [ ],
        "html" : "<p>Normal DPD activity and &quot;normal&quot; risk for fluoropyrimidine toxicity.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 8
    }, {
      "id" : 1448589737,
      "history" : [ {
        "id" : 1448589735,
        "date" : "2017-02-06T10:21:33.596-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589736,
        "externalLinks" : [ ],
        "html" : "<p>Normal Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Normal Metabolizer",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1446441324,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986594,
        "externalLinks" : [ ],
        "html" : "<p>Homozygous for normal activity alleles (normal function alleles); high DPD activity.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Homozygous for normal activity alleles (normal function alleles); high DPD activity.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 11
    }, {
      "id" : 1446441386,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986596,
        "externalLinks" : [ ],
        "html" : "<p>Use label-recommended dosage and administration.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Use label-recommended dosage and administration.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 8
    } ],
    "genePhenotypes" : [ "DPYD:Normal Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166109594",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166109594",
      "name" : "CPIC Guideline for capecitabine and DPYD",
      "version" : 78
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501931",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501931,
      "resource" : "Guideline Strength",
      "term" : "Moderate",
      "termId" : "guidelineStrength:981501931",
      "version" : 0
    },
    "version" : 24
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128873",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128873",
    "name" : "Intermediate Metabolizer",
    "annotations" : [ {
      "id" : 1446441267,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986592,
        "externalLinks" : [ ],
        "html" : "<p>Decreased DPD activity (leukocyte DPD activity at 30-70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Decreased DPD activity (leukocyte DPD activity at 30-70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 8
    }, {
      "id" : 1448589741,
      "history" : [ {
        "id" : 1448589739,
        "date" : "2017-02-06T10:24:09.208-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589740,
        "externalLinks" : [ ],
        "html" : "<p>Intermediate Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Intermediate Metabolizer",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1446441219,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986591,
        "externalLinks" : [ ],
        "html" : "<p>Heterozyogous; intermediate DPD activity, at risk for toxicity with drug exposure.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Heterozyogous; intermediate DPD activity, at risk for toxicity with drug exposure.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 10
    }, {
      "id" : 1446441310,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986593,
        "externalLinks" : [ ],
        "html" : "<p>Start with at least a 50% reduction in starting dose, followed by titration of dose based on toxicity (increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities) or pharmacokinetic test (if available).</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Start with at least a 50% reduction in starting dose, followed by titration of dose based on toxicity (increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities) or pharmacokinetic test (if available).",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 8
    } ],
    "genePhenotypes" : [ "DPYD:No Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166109594",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166109594",
      "name" : "CPIC Guideline for capecitabine and DPYD",
      "version" : 78
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501931",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501931,
      "resource" : "Guideline Strength",
      "term" : "Moderate",
      "termId" : "guidelineStrength:981501931",
      "version" : 0
    },
    "version" : 21
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128874",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128874",
    "name" : "Poor Metabolizer",
    "annotations" : [ {
      "id" : 1446441048,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986590,
        "externalLinks" : [ ],
        "html" : "<p>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 10
    }, {
      "id" : 1448589733,
      "history" : [ {
        "id" : 1448589731,
        "date" : "2017-02-06T10:19:17.401-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589732,
        "externalLinks" : [ ],
        "html" : "<p>Poor Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Poor Metabolizer",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1446441018,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986589,
        "externalLinks" : [ ],
        "html" : "<p>Homozygous for deficient activity alleles (no function alleles); DPD deficiency.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Homozygous for deficient activity alleles (no function alleles); DPD deficiency.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 11
    }, {
      "id" : 1446440991,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986588,
        "externalLinks" : [ ],
        "html" : "<p>Select alternative drug.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Select alternative drug.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 8
    } ],
    "genePhenotypes" : [ "DPYD:No Function/No Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166109594",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166109594",
      "name" : "CPIC Guideline for capecitabine and DPYD",
      "version" : 78
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 24
  } ],
  "genePhenotypes" : {
    "DPYD" : {
      "*1" : "Normal Function",
      "*2A" : "No Function",
      "*3" : "Probable Decreased Function",
      "*4" : "Normal Function",
      "*5" : "Normal Function",
      "*6" : "Normal Function",
      "*7" : "Probable Decreased Function",
      "*8" : "Probable Decreased Function",
      "*9A" : "Normal Function",
      "*9B" : "Probable Decreased Function",
      "*10" : "Probable Decreased Function",
      "*11" : "Probable Decreased Function",
      "*12" : "Probable Decreased Function",
      "*13" : "No Function",
      "rs67376798A" : "No Function"
    }
  }
}